OPTIBUMIN
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 20 Dec 2024)
What this means for you
Registered since 14 May 2019. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88095267
- Registration number
- 5749521
- Mark type
- Design + words
- Filed
- 28 Aug 2018
- Published for opposition
- 26 Feb 2019
- Registered
- 14 May 2019
- Attorney of record
- Crissa A. Seymour Cook
Goods and services
- Class 001 — Chemicals: Recombinant albumin in the nature of excipients for use in the manufacture of pharmaceutical preparations, cellular therapies, gene therapies and vaccines; Recombinant albumin for use as a reagent for scientific and research use, namely, biomedical research and development
- Class 005 — Pharmaceuticals: Recombinant albumin for biological therapeutic purposes; Recombinant albumin for use as a reagent for medical use, namely, in-vitro fertilization, tissue sealant, tissue and cell cryopreservation, and blood detoxification
Owner
- INVITRIA, INC., JUNCTION CITY, KS, US
- Ventria Bioscience Inc., Junction City, KS, US
- Ventria Bioscience Inc., Junction City, KS, US
- Ventria Bioscience Inc., Junction City, KS, US
Prosecution history
- 20 Dec 2024 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 20 Dec 2024 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 20 Dec 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 22 Jul 2024 — TEAS SECTION 8 & 15 RECEIVED
- 14 May 2024 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 13 Sept 2023 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 14 May 2019 — REGISTERED-PRINCIPAL REGISTER
- 26 Feb 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Feb 2019 — PUBLISHED FOR OPPOSITION
- 06 Feb 2019 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Jan 2019 — ASSIGNED TO LIE
- 04 Jan 2019 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 03 Jan 2019 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 02 Jan 2019 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 02 Jan 2019 — TEAS RESPONSE TO OFFICE ACTION RECEIVED